A Comparative Study of Lobaplatin and Cisplatin in the Treatment of Advanced Ovarian Cancer Undergoing Hypertherimic Intraperitoneal Chemotherapy Combined with Intravenous Chemotherapy

Abstract

Purpose: To explore and compare the curative effect and side effects of the patients
with epithelial cell ovarian carcinoma after surgery administered by hyperthermic
intraperitoneal chemotherapy (HIPEC) with lobaplatin combined with intravenous
chemotherapy. Method: Forty patients with epithelial cell ovarian carcinoma treated by
HIPEC and systemic chemotherapy after CRS were selected from January 2012 to September2014, and were divided into two group, Group Lobaplatin and Group Cisplatin, according to the kind of platinum used in HIPEC. The general information, 1,3-year survival rate, serum CA125 level and adverse events were recorded. Result: As for the 1,3-year survival rate, serum CA125 level, there is no statistical difference comparing data of two groups. As for adverse events between two groups, the occurring of nausea, vomiting and abdominal pain of the lobaplatin group is significantly lower than that of the cisplatin group. Conclusion: Hyperthermic intraperitoneal chemotherapy with Lobaplatin in combination with intravenous chemotherapy is effective and feasible treatment for patients with advanced ovarian carcinoma. Lobaplatin and cisplatin both have acceptable complication rate and survival rate. According to our study, patients in lobaplatin group have better compliance than cisplatin.